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Abstract 
Background: CRISPR-Cas9 genome editing and labeling has emerged as an important tool in biologic research, par-
ticularly in regards to potential transgenic and gene therapy applications. Delivery of CRISPR-Cas9 plasmids to target 
cells is typically done by non-viral methods (chemical, physical, and/or electrical), which are limited by low transfec-
tion efficiencies or with viral vectors, which are limited by safety and restricted volume size. In this work, a non-viral 
transfection technology, named lance array nanoinjection (LAN), utilizes a microfabricated silicon chip to physi-
cally and electrically deliver genetic material to large numbers of target cells. To demonstrate its utility, we used the 
CRISPR-Cas9 system to edit the genome of isogenic cells. Two variables related to the LAN process were tested which 
include the magnitude of current used during plasmid attraction to the silicon lance array (1.5, 4.5, or 6.0 mA) and the 
number of times cells were injected (one or three times).
Results: Results indicate that most successful genome editing occurred after injecting three times at a current con-
trol setting of 4.5 mA, reaching a median level of 93.77 % modification. Furthermore, we found that genome editing 
using LAN follows a non-linear injection-dose response, meaning samples injected three times had modification rates 
as high as nearly 12 times analogously treated single injected samples.
Conclusions: These findings demonstrate the LAN’s ability to deliver genetic material to cells and indicate that suc-
cessful alteration of the genome is influenced by a serial injection method as well as the electrical current settings.
Keywords: Lance array nanoinjection, CRISPR-Cas9, Gene knock-out, Serial injection, Current control, Non-viral 
transfection
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Background
The creativity and scale with which researchers are uti-
lizing clustered regularly interspaced short palindromic 
repeat (CRISPR) sequences and Cas9 (CRISPR-associ-
ated) proteins for genomic editing has led to an explo-
sion of possibilities in both transgenic research and gene 
therapy applications (Feng et  al. 2015; Horii et  al. 2013; 
Li et  al. 2015; Mou et  al. 2015; Nicholson et  al. 2015; 
Petersen and Niemann 2015; Seruggia and Montoliu 
2014). Three major elements fueling this movement 
include the target versatility and ease with which 
researchers can generate CRISPR-Cas plasmids (Ran 
et al. 2013), the ability to modify multiple genomic loca-
tions in a single step (Ousterout et al. 2015; Wang et al. 
2013), and the ability to do so at rates difficult to obtain 
using other editing methods such as transcription acti-
vator-like effector nucleases (TALEN) (Ding et  al. 2013; 
Pennisi 2013).
Despite the great potential CRISPR/Cas9 plasmids 
offer, there are limitations that make delivering molecu-
lar loads to target cells challenging for widespread appli-
cation. Commonly used viruses, such as adenoviruses, 
adeno-associated viruses, and lentiviruses, are known 
for having high transfection rates (Deyle and Russell 
Open Access
*Correspondence:  sandrahope2016@gmail.com 
2 Department of Microbiology and Molecular Biology, Brigham Young 
University, Provo, UT, USA
Full list of author information is available at the end of the article
Page 2 of 11Sessions et al. SpringerPlus  (2016) 5:1521 
2009; Matrai et  al. 2010). However, adenoviruses cause 
excessive immune reactions (Ritter et  al. 2002), adeno-
associated viruses can cause insertional mutagenesis 
(Deyle and Russell 2009), and lentiviruses can cause both 
immune reactions and insertional mutagenesis (Follenzi 
et  al. 2007; Hacein-Bey-Abina et  al. 2003; Matrai et  al. 
2010; VandenDriessche et  al. 2002). While CRISPR-
Cas9 provides an elegant method to by-pass many of the 
concerns related to insertional mutagenesis (Zhou et al. 
2014), viruses are still constrained by payload capacity 
(Gardlik et al. 2005), which could limit utility.
In an effort to address concerns raised with viral trans-
duction, researchers have put emphasis on developing 
chemical, physical, and/or electrical transfection tech-
nologies aimed at producing a robust delivery method in 
terms of effective delivery and expression without com-
promising cell viability (Itaka and Kataoka 2009; Park et al. 
2010; van Gaal et al. 2011). Unfortunately, the trade-off for 
using non-viral approaches has resulted in lower transfec-
tion rates (Mellott et  al. 2013) and additional challenges, 
such as genetic load transfer and preservation across 
both the cell and nuclear membranes (Ferrari et al. 2002; 
Ferrer-Miralles et al. 2008; Kodama et al. 2006; Lungwitz 
et  al. 2005; Pouton and Seymour 2001). Commonly used 
chemical methods, such as cationic lipids and polymers, 
can be effective in transfection (Baoum et al. 2010, 2012; 
Baoum and Berkland 2011) (although not as effective as 
viral modalities (Godbey and Mikos 2001; Godbey et  al. 
1999; Green et al. 2008; Jo and Tabata 2008; Merdan et al. 
2002; Middaugh and Ramsey 2007; Midoux et  al. 2009; 
Park et  al. 2006)), but are also potentially toxic to cells 
because of dosage requirements, usually require optimiza-
tion experimentation for each cell type, and do not work in 
all cell lines (Mellott et al. 2013; Wiethoff and Middaugh 
2003). Physical methods like microinjection and electri-
cal methods like electroporation can be effective (Mehier-
Humbert and Guy 2005), but often are traumatic to the 
target cells, reducing cell viability (Mellott et al. 2013).
Recently, a new non-viral transfection technology, 
known as lance array nanoinjection (LAN) was intro-
duced which was designed with many of these challenges 
in mind. LAN uses a microfabricated silicon etched array 
of lances to physically penetrate hundreds of thousands 
of cells simultaneously and electrically deliver attached 
molecular loads (Lindstrom et  al. 2014; Sessions et  al. 
2014; Teichert et al. 2013) (see Fig. 1). Built upon a first 
generation technology used to create transgenic mice 
(Aten et  al. 2011, 2012; Wilson et  al. 2013), LAN inter-
acts directly with the molecular load via electrical inter-
actions, thereby eliminating viral-induced immune 
responses and carrier-vehicle cytotoxicity issues. Fur-
thermore, LAN creates transient pores between 1 and 
2.5  µm in diameter (making it possible to deliver large 
loads) and it has cell survival rates of 78–91 % post-injec-
tion (Lindstrom et al. 2014).
In this report, we extend previous work by combin-
ing LAN with CRISPR-Cas9 technology. To do this, a 
CRISPR-Cas9 plasmid was designed to knock-out (KO) 
constitutive green fluorescent protein (GFP) expres-
sion in HeLa cells via Non-Homologous End-Joining 
(NHEJ) repair. Two major variables explored in this work 
included: the current-control setting used during the ini-
tial attraction of DNA to the silicon lances prior to cell 
membrane penetration (1.5, 4.5, and 6.0  mA) and the 
number of times samples were injected (one time, x1; 
three times, x3). We report that cells injected x3 had a 
significantly higher number of cells with GFP knocked-
out when compared to samples x1 injected samples and 
that the injection-dose response was non-linear. Also, it 
was observed that an intermediate current control set-
ting (4.5 mA) used during the LAN process produced the 
greatest percentage of living, GFP negative HeLa cells.
Methods
Lance array nanoinjection of cells
For injections, cells were seeded on coverslips and 
mounted on a platform in a well filled with media. DNA 
was added to the well with the lance array positioned 
above the cells. Upon DNA attraction to the lance tips 
using an electrical charge, the lance array was injected 
into the cells on the coverslip. Once the lance tips pen-
etrated the cell membrane, the charge on the lance tips 
reversed to release DNA according to the experimental 
group defined below. After removing the lance array, 
the coverslip with injected cells was then removed from 
the injection well and placed in a culture dish until cells 
were harvested and flow cytometry readings were taken 
to determine the ability of the injected CRISPR DNA to 
knock out expression of the gene of interest.
GFP+/FRT HeLa cell line
We generated an isogenic cell line containing a single copy 
of EGFP (enhanced green fluorescent protein) by cloning 
the code sequence of EGFP into pCDNA5/FRT and intro-
ducing this plasmid into HeLa/FRT cells in the presence 
of Flip recombinase (Flp-In System, Life Technologies, 
Carlsbad, CA). Hygromycin selected HeLa cells expressed 
99 % GFP and were grown in Dulbeccos Modified Eagles 
Medium (DMEM, Life Technologies, Carlsbad, CA) with 
10 % Fetal Bovine Serum (FBS, Denville Scientific, Hollis-
ton, MA) and streptomyocin/penicillin (Gibco, Waltham, 
MA) and incubated at 37 °C and 5 % carbon dioxide.
CRISPR plasmid
In order to facilitate GFP knock-out in the GFP+/FRT 
HeLa cell line, a CRISPR-Cas9 plasmid was constructed 
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using sgRNA primers directed towards the N-terminus 
of EGFP, which would disrupt GFP production via NHEJ 
repair inaccuracies (Mali et al. 2013; Ran et al. 2013).
The CRISPR-Cas9 GFP knock-out plasmid was cre-
ated by preparing and ligating sgRNA GFP oligos to a 
pSpCas9(BB)-2A-Puro (PX459) plasmid, a gift from Feng 
Zhang (Addgene plasmid #48139) (Ran et al. 2013). The 
top and bottom oligos were prepared to be inserted into 
the pSpCas9(BB)-2A-Puro plasmid using protocol previ-
ously described in the literature (Ran et al. 2013). Top10 
cells were then transformed with plasmids using a stand-
ard transformation protocol. DNA was amplified and 
extracted from the Top10 cells following the protocols of 
Qiagen Maxi and Mega prep kits (Qiagen, Valencia, CA).
Injection set‑up
The LAN device used for injections is comprised of five 
major components which include: silicon-etched lance 
array, orthoplanar spring and mount, cell culture plat-
form, stepper motor and threaded screw, and electrical 
switch box. Figure  2 illustrates the interactions of these 
components and provides a context to the LAN process.
Silicon‑etched lance, orthoplanar spring and mount
The LAN device contains a microfabricated silicon wafer 
with etched lances (Fig.  1) attached to an orthoplanar 
spring which has the stepper motor mounted on top 
(Fig. 2). The lance array serves to physically penetrate cell 
membranes and also to electrically interact with DNA. 
The orthoplanar spring has an attachment on its bottom 
surface for the silicon lance chip to be inserted, thereby 
providing vertical motion required for injection as well 
as the electrical connections. Construction of both the 
lance array and the orthoplanar spring are discussed in 
prior literature (Teichert et al. 2013; Teichert and Jensen 
2013).
Cell culture platform
The cell culture platform consists of three individual 
pieces: two PLA 3D printed platform pieces (Maker-
Bot Replicator 2, MakerBot, Brooklyn, NY) (snap-fit 
together) and the glass slide (contains adhered cells). The 
system is designed such that the glass slide can be assem-
bled into the cell culture platform during injection, which 
helps with alignment of the orthoplanar spring/lance 
array attachment. Following injection, the glass slide can 
be easily removed from the assembly for incubation.
Stepper motor and threaded screw
The stepper motor is shown in Fig.  2 as a component 
attached to the top surface of the orthoplanar spring 
and serves as an actuator of the spring in orchestration 
with the electrical input signals delivered to the silicon 
lances. The stepper motor is controlled by an Arduino 
Uno (Small Projects, Somerville, MA) and has been cali-
brated to vertically operate the threaded screw insert at 
160 µm/s.
Electrical box
The electrical box is designed to take electrical input sig-
nals from three different power sources (Keithley 2400, 
Cleveland, OH) and to output them to the two electrical 
leads; one lead passing through the upper portions of the 
injection device to supply charge to the lance array, and 
another lead passing through the cell culture platform to 
act as a counter-electrode beneath the cell culture. Fig-
ure 2 describes the electrical conditions supplied by the 
electrical box during the four phases of the injection pro-
cess. The timing of the electrical signal delivery to the 
nanoinjection device is controlled by an Arduino Uno.
Testing preparation
GFP Positive/FRT HeLa cells were prepared approxi-
mately 24  h in advance on 18  mm by 18  mm glass 
slides contained in six well plates. The n-number for an 
experimental group refers to the number of individual 
glass slides subjected to the treatment and analysis as 
described below. Cells were incubated during this period 
at 37C, 5  % carbon dioxide, and supplied with 2  mL of 
DMEM with 10  % FBS and streptomyocin/penicillin. 
Fig. 1 Isometric projection of silicon etched lance array taken by 
scanning electron microscope. Lances measure 8–10 µm in length 
and 1–2.5 µm in diameter. Spacing of lances from center-to-center 
measure 10 µm in both planar directions in a grid of 2000 by 2000 
lances per chip
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Cells cultures on the glass slides were approximately 70 % 
confluent.
Following this 24  h incubation, the HeLa cells were 
snapped into the 3D-printed cell culture platforms. Follow-
ing transfer to the platforms, cells were supplied with 2 mL 
of fresh DMEM and 4 µL of 25 mM chloroquine and then 
incubated for an additional 15 min. After being pre-treated 
with chloroquine, DMEM was removed and 2 mL of phos-
phate buffered solution (PBS, Gibco, Waltham, MA) was 
added. Incubation for an addition 15 min followed.
Immediately prior to injection, treatment samples were 
supplied with the CRISPR-Cas9 plasmid at a concentra-
tion of 750 ng of DNA/mL of PBS injection solution.
Post testing flow cytometry preparation
Following injection, all samples had their glass slides 
removed from 3D-printed cell culture platforms and 
placed into six-well plates with 2 mL of DMEM. All treat-
ment samples were then incubated for a period of 7 days 
to allow the existing GFP to be lost from cells.
After 7 days of incubation, all samples were trypsinized 
with 0.5 mL of 5× trypsin (Sigma Aldrich, St. Louis, MO) 
per well and incubated for 5 min. Trypsin was then deac-
tivated with 1.5 mL of DMEM per well and then trans-
ferred to FACS tubes for centrifugation for 10  min at 
2000  rpm. Following centrifugation, samples’ superna-
tant were removed and cells were re-suspended in 0.5 mL 
of PBS with 80 µL of propidium iodide (PI, 500 µg/mL; 
Sigma Aldrich, St. Louis, MO). The PI served as a viabil-
ity stain for selecting living cells from dead cells in post 
flow cytometry analysis.
Flow cytometry
All samples were quantified using flow cytometry 
(Attune Acoustic Focusing Flow Cytometer, Life Tech-
nologies, Carlsbad, CA). Prior to flow, appropriate single 
color samples were generated for GFP and PI in order to 
compensate for signal cross-over. Each sample was then 
run and had approximately 20,000 events counted and 
characterized.
Fig. 2 Diagram of the LAN set-up. On the left, the four phases of the LAN process in terms of electrical parameters and physical events are 
described. Illustration of the connection of the stepper motor to the orthoplanar spring is shown on the right. With the lance array pointed down-
ward, during the injection process, the lances are inserted into cultured cells secured on the cell culture platform
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Using Attune’s post-processing software, samples were 
gated based on PI signals for living vs dead cells. Using 
only the living cell populations, samples were then gated 
based on the GFP signal in order to characterize the effi-
cacy of the CRISPR-Cas9/LAN knock-out of GFP. Refer 
to Fig. 3 for example flow cytometry results based on the 
gating procedure described.
Statistical analysis
Data gathered from flow cytometry was analyzed sta-
tistically in JMP (SAS, Cary, NC) using an ANOVA test 
(F-ratio =  48.0318) and Student t tests (α =  0.05). The 
efficiency statistic reported in the “Results” section is 
based on number of living GFP Negative cells in each 
sample. Of note, based on the hypotheses that the sam-
ples injected three times will be greater than or equal 
to the samples injected once, t tests involving the com-
parison of the controls to treatment groups or treat-
ment groups against one another, a one-tailed p value is 
reported.
Samples were allowed to incubate for 7  days post-
injection to ensure GFP degradation. Due to this long 
period of time for cell division, cells were passed in order 
to prevent crowding on the cover slips; therefore, rela-
tive viability rates from the injection are not available. 
Expression data is reported as a percentage of the living 
cells in the final sample harvested at 7  days. For con-
text of viability rates following LAN, other works have 
reported viability rates post-injection between approxi-
mately 75–90 % (Sessions et al. 2014).
Results
Ten experimental groups were created in order to charac-
terize the effects that the number of injection events and 
the current control settings used during LAN would have 
on GFP knock-out in the GFP Positive/FRT HeLa cells. 
Four of these groups were controls, which consisted of: 
Non-Treated Controls (NTC)—received no injection, 
no applied current/voltage, and no DNA; Background 
Controls for nanoinjection (BC)—received DNA, but no 
applied electrical protocols or physical injection; Nega-
tive Controls for electrical exposure (NC)—received 
physical injection, but with no applied electrical pro-
tocols or DNA; and lastly Diffusion Controls (DC)—
received physical injection and DNA, but no applied 
electrical protocol.
Treated samples make up the other six experimen-
tal groups. Single Injection (x1) samples were physically 
injected only one time under the following conditions:
a. Phase 1: 20 s application of 1.5, 4.5, or 6.0 mA across 
lance array (performed with lances external to cell) 
for the purpose of DNA collection on the lance.
b. Phase 2: Lance array inserted into cell culture and 
pulsed with 10 square-wave pulses of amplitude 
between 0 and −7 V for 20 ms.
c. Phase 3: Directly following pulsing, a 5  s period of 
−1.5 V DC is applied
d. Phase 4: Lance array is removed from the cells.
Multiple Injection (x3) samples were Injected under 
the same conditions as described for Single Injections 
(x1) with the exception that following the first injection, 
cell cultures were placed back into the incubator for 1 h 
before injecting again. This process was repeated for a 
total of 3 injection events into the same cell culture.
For convenience with treatment sample nomencla-
ture, specific experimental groups will be referred to by 
the current control setting used during Phase 1 and the 
number of times the sample was injected. For instance, 
1.5 mA, x1 means that the sample received 1.5 mA dur-
ing Phase 1 and the samples were nanoinjected only once.
Multiple LAN injections are more effective than one 
injection
The construction of the HeLa cell line was noted earlier, 
and consisted of a pFRT/laczeo HeLa cell line (Flp-In Sys-
tem, Life Technologies) which was purchased and trans-
fected with a pcDNA5/FRT expression vector containing 
both the gene of interest and means to facilitate its pro-
duction, which include: a green fluorescent protein (GFP) 
gene, a CMV promoter, and a FRT site. The FRT site is 
situated upstream of the compliment ATG sequence for 
the hygromycin gene found in the Flp-In host HeLa cell 
line. Co-transfection with the pOG44 vector expresses 
the flip recombinase machinery that allows the pcDNA5/
FRT to flip into the pFRT/laczeo HeLa cell line, thereby 
making the hygromycin gene in the HeLa cells func-
tionally complete. Once both transfection events were 
accomplished, HeLa cells that successfully had flipped-
in the GFP gene at the FRT site could be selected by 
hygromycin.
The construction of the CRISPR-Cas9 plasmid was 
noted earlier, and consisted of a pSpCas9(BB)-2A-Puro 
(PX459) plasmid, a gift from Feng Zhang (Addgene plas-
mid #48139) (Ran et  al. 2013) that was modified with 
oligos that code for sgRNA that directs Cas9 to the FRT 
site to disrupt GFP production via NHEJ. If the CRISPR-
Cas9 GFP knock-out plasmid is successful in disrupting 
the GFP gene at the targeted FRT site, the HeLa cells will 
become GFP negative because these HeLa cells only have 
a single GFP gene.
Table  1 summarizes the flow cytometry results of the 
respective experimental groups demonstrating the dis-
ruption of the GFP gene. Two key findings were noted in 
regards to the number of injections and transfection rates. 
Page 6 of 11Sessions et al. SpringerPlus  (2016) 5:1521 
First, the transfection rates for the x3 injected samples 
are significantly higher than the x1 injected samples, with 
the 4.5  mA, x3 treatment samples achieving the highest 
observed mean knock-out with a median GFP knock-out 
efficiency of 93.77  % (see Table  1). Figure  3 provides an 
example of the flow cytometry results from each experi-
mental group used to obtain the data in Table 1.
Data collected from flow cytometry and analyzed in 
JMP represents mean and median GFP KO rates for the 
respective sample types. The percentage of cells success-
fully transfected is calculated as the number of living and 
GFP negative cells divided by the number of living cells in 
each sample.
Second, Table  2 demonstrates that a large difference 
was observed between mean values for all experimen-
tal groups when examining the effect of the number of 
injections as determined by flow (Fig. 3). The largest dif-
ference was observed in the 1.5 mA samples, exhibiting 
a change of 59.87  % when comparing x1 to x3 injected 
samples. When viewed in context of Table 1, it is noted 
that the injection-dose response of all treatment samples 
is non-linear, meaning the rate of GFP knock-out did not 
follow a linear scale with the number of times cells were 
injected. In the case of the 1.5  mA current controlled 
samples, the single injection mean transfection rate is 
6.11 %. On a linear scale, the predicted value for samples 
Fig. 3 Flow cytometry analysis to determine gene expression changes. Histograms of raw data were divided to determine the number of GFP neg-
ative (left side) and GFP positive (right side) cells on the plot for each sample. The number of cells expressing GFP did not decrease in control samples 
(a–d). Side-by-side, experimental samples exhibited a significant increase in GFP negative cells when injected three times (LANx3) compared to 
cells injected once (LANx1) in 1.5 mA injections (e, f), 4.5 mA injections (g, h), and 6.0 mA injections (i, j). Compare to data in Table 1 and Fig. 4
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injected three times should be roughly 18.33 %. Instead, 
for 1.5 mA, x3 treatment samples the transfection rate is 
72.78 %, nearly 4 times greater than the linear predicted 
value. Similar but less pronounced observations were 
made in the case of the 4.5 and 6.0 mA samples, resulting 
in differences in linear predictions and observed mean 
transfection rates of 14.67 and 2.06 %, respectively.
Represented data was initially screened in JMP using 
ANOVA test to determine presence of statistically sig-
nificance relationships followed by one-sided t test 
(α =  0.05) evaluation of specific comparisons using the 
full data set. All represented relationships are statistically 
different.
Mid‑range current control yielded the highest observed 
knock‑out
Results in Table  3 show the statistical comparisons 
between sample types, grouped according to the num-
ber of times the samples were injected. While it is of 
note that there were no intra-group comparisons that 
were statistically significant in regards to current control 
effects on GFP knock-out (with the exception of 1.5 mA, 
x1 vs 6.0 mA, x1 injections), the relative position of the 
median values (Table 1) for both the single and multiple 
injection groups appears to favor the 4.5 mA treated sam-
ples. The data suggests that using an intermediate current 
control setting during injection may improve transfection 
efficiency.
Discussion
Much like other transfection methods, the designed 
intent of LAN is to direct genetic loads into target cells 
without threatening their survival. Noted earlier, viruses 
have been a mainstay in transfection protocols because 
of the higher transfection rates that can be achieved rela-
tive to non-viral modalities (Mellott et al. 2013). LAN is a 
non-viral method designed to address this short-coming 
by generically delivering any electrically charged molec-
ular load by electrostatic attraction and release into the 
intracellular space of target cells via small micron-sized 
lance structures.
This process of electrical interaction with genetic 
material and physical penetration of the cell membrane 
was originally created for mouse embryonic trans-
genic research using a microelectromechanical system 
(MEMS)-based single silicon lance (Aten et  al. 2008). 
Using this device, it was shown that nanoinjection had 
comparable transfection rates to microinjection but 
increased embryo survival rates (Aten et  al. 2012). This 
delivery system was particularly useful because injections 
merely needed to be cytoplasmic due to the localized 
electroporative effect of the lance on the pronuclei—an 
event termed intracellular electroporetic nanoinjection 
(IEN) (Wilson et al. 2013).
Later, nanoinjection was extended to somatic cell tar-
gets by utilizing an array of silicon etched lances, a design 
used in this work. Electrostatic principles used to initially 
determine DNA behavior with the single lance injec-
tor (Aten et  al. 2011; David et  al. 2010) have been also 
applied in LAN, both structurally (Teichert et  al. 2013; 
Teichert and Jensen 2013) and procedurally (Lindstrom 
et al. 2014; Sessions et al. 2014).
Initial experimentation with LAN was designed to 
show the effectiveness with which small molecules (such 
as propidium iodide, PI) could be delivered to cultured 
cells and what impact injection would have on survival. 
As mentioned in the materials and methods section, 
relative viability rates from this study are not available 
because cells incubated 7 days post-injection divide to the 
extent that the original cell death would not be observ-
able. To give a context of cell survival for this study, 
previous results demonstrated a voltage–dependent rela-
tionship for injection success, while maintaining viabil-
ity rates between 78 and 91  % (Lindstrom et  al. 2014). 
Table 1 LAN Statistical summary of  the sample types 
and associated GFP KO rates
Data collected from flow cytometry and analyzed in JMP represents mean 
and median GFP KO rates for the respective sample types. Percentage of cells 
successfully transfected is calculated as the number of living and GFP negative 
cells divided by the number of living cells in each sample
Sample type Sample size (n) Mean GFP KO 
percent (%)
Median GFP KO 
percent (%)
NTC 21 5.27 5.37
NC 26 3.92 3.62
BC 18 5.96 5.37
DC 23 4.04 3.82
1.5 mA, x1 16 6.92 6.11
4.5 mA, x1 8 21.63 17.37
6.0 mA, x1 16 22.65 8.45
1.5 mA, x3 20 66.79 72.78
4.5 mA, x3 27 79.56 93.77
6.0 mA, x3 20 70.01 70.32
Table 2 One-sided T test results from comparisons of mul-
tiple (x3) versus single (x1) injected samples
Represented data was initially screened in JMP using ANOVA test to determine 
presence of statistically significance relationships followed by one-sided t 
test (α = 0.05) evaluation of specific comparisons. Default minimum p value 
reported is 0.0001. All represented relationships are statistically different
Multiple injections (1)  
versus single injections (2)
P value Difference in mean  
GFP KO (1–2) (%)
1.5 mA, x3 versus 1.5 mA, x1 <0.0001 59.87
4.5 mA, x3 versus 4.5 mA, x1 <0.0001 57.93
6.0 mA, x3 versus 6.0 mA, x1 <0.0001 47.36
Page 8 of 11Sessions et al. SpringerPlus  (2016) 5:1521 
Similar results were obtained using LAN in experimenta-
tion designed to assess the effects of different saline solu-
tion types used during injection (Sessions et al. 2014).
This current work marks the first LAN proof-of-con-
cept results regarding the use of CRIPSR-Cas9 plasmids 
to knock-out gene function. Table  1 indicates that the 
maximum median GFP KO efficiencies of 70.32–93.77 % 
can be achieved using LAN after injecting HeLa cells 
three times.
Contextually, these LAN efficiencies are encourag-
ing because high-throughput screening of the human 
genome using CRISPR-Cas9 plasmids designed to knock-
out (KO) gene function have proven to be critical to 
understanding gene function (Zhou et al. 2014). Maggio 
et  al. (2014) recently demonstrated the KO behavior of 
CRISPR-Cas9 using adenoviral vector delivery of gRNA 
and Cas9 in two separate vectors. Designed to target 
the AAVS1 “safe harbor” locus in a panel of human cells 
types which include: cervix carcinoma HeLa cells, osteo-
sarcoma U2OS cells, hMSCs, and myoblasts, this team 
showed relative gene KO when increasing amounts of the 
two vectors were applied. In the case of HeLa cell experi-
mentation, Maggio et al. achieved maximum gene KO of 
31 % when 100 TU/cell of both vectors, an efficiency rate 
less than a third of the maximum efficiency reported here 
using LAN in the same cell type. While our study did not 
provide a direct comparison between the two methods 
of transfection, the data is compelling towards further 
development of the LAN as a new technology in deliver-
ing genetic material into cells.
In addition to exhibiting high knock-out efficiency 
rates, this work also shows in Fig. 4 the non-linear differ-
ence between the x1 and x3 injected samples, a behavior 
not previously noted in LAN. For example, 1.5  mA, x1 
samples had a median KO rate of 6.11 %, while 1.5 mA, 
x3 samples had a median KO rate of 72.78 %, a rate nearly 
12 times higher. While the magnitudes are not as high for 
the other sample comparisons, the non-linear trend is 
still present.
One possible explanation for this behavior is related 
to cellular response to cell membrane defects, such as 
defects created by lance induced pores. When a surface 
defect occurs in a cell membrane, the cell responds by 
attempting to mobilize and remodel structural elements 
such as actinomyosin, microtubules, and the cell mem-
brane by contracting around the wound and allowing 
repair machinery to close membrane gaps (Abreu-Blanco 
et al. 2011a, b). In LAN samples that experience multiple 
injections, one possible explanation for increased GFP 
KO is that repair mechanisms may be delayed because 
of prior insults still being repaired. If true, saturation of 
repair mechanisms would permit longer periods of time 
for CRISPR-Cas9 plasmid movement into the cell follow-
ing multiple injection treatments, and thereby allowing 
greater GFP KO. While this idea potentially explains why 
greater plasmid delivery may be possible, it does assume 
that diffusion is a major factor in plasmid motion across a 
cell membrane following LAN, a behavior that is not sup-
ported by the diffusion controls (DC) used in this study.
Another explanation for the increased GFP KO with 
samples injected x3 is related to how quickly the tar-
get cells remove the delivered plasmid. Prior to injec-
tion, samples are pre-treated with chloroquine, an agent 
designed to inhibit lysosomal action, to increase the 
half-life of the plasmid in the cytoplasm of target cells. 
It is possible that initial dosing of plasmids into target 
cells during the first injection event is enough to satu-
rate functional lysosomes such that when additional 
plasmids are delivered in subsequent injection events, 
higher levels of functional CRISPR-Cas9 plasmids are 
available to disrupt GFP gene function. Again, this idea 
has not been defined in prior work and requires further 
investigation.
Another behavior noted in regards to non-linear KO 
rates deals with the current control exposure during 
Phase 1. Noted in Table  1 is the fact that 1.5  mA sam-
ples experience the greatest increase in GFP KO from x1 
injection treatment to x3 injection treatment (mean dif-
ference of 59.87 %). It has been noted in previous work 
that lower applied electrical conditions during LAN con-
tribute to higher cell viability rates (Sessions et al. 2014). 
It is believed that the because the 1.5 mA, x3 treatment 
samples received a reduced electrical exposure during 
injection, that more successfully transfected cells sur-
vived to be GFP negative than the 4.5 and 6.0 mA treated 
samples. If that were the case, samples exposed to 1.5 mA 
Table 3 One-sided T test results from intra-group comparisons (by number of times injected)
Represented data was initially screened in JMP using ANOVA test to determine presence of statistically significance relationships followed by one-sided t test 
(α = 0.05) evaluation of specific comparisons. Default minimum p value reported is 0.0001
Only one statistically significant relationship was identified between the 1.5 mA, x1 and 6.0 mA, x1
Single (x1) injected comparisons P value Multiple (x3) injected comparisons P value
1.5 mA, x1 versus 4.5 mA, x1 0.0684 1.5 mA, x3 versus 4.5 mA, x3 0.0985
1.5 mA, x1 versus 6.0 mA, x1 0.0093 1.5 mA, x3 versus 6.0 mA, x3 0.3454
4.5 mA, x1 versus 6.0 mA, x1 0.4621 4.5 mA, x3 versus 6.0 mA, x3 0.8895
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would more likely survive the injection process and 
thereby potentially increase the transfection rate.
Intertwined in the discussion of the non-linear behav-
ior of the GFP KO rates when comparing x1 injections to 
x3 injections is the fact that mid-range current controlled 
samples had the best median GFP KO. It is observed in 
Table  2 that the 1.5  mA samples experience the great-
est change in GFP KO from x1 to x3 injected samples (a 
difference of 59.87 %), while overall the 4.5 mA samples 
experience the greatest magnitude in GFP KO, reaching 
a median value of 93.77 % for the x3 injected treatment 
group. A possible explanation for this behavior is that 
4.5 mA protocols offers the best balance between effec-
tive electrical attraction/release of the DNA during the 
LAN process, while being a mild stressor in terms of cell 
viability. Even though the 1.5  mA protocol is milder in 
terms of cellular stress, a feature seen in electroporation 
studies to improve cell viability (Canatella et  al. 2001), 
perhaps the 4.5  mA protocol is better at balancing the 
cellular stress with effective attraction and release of the 
DNA, a parameter shown to increase DNA motion when 
done at higher magnitudes in processes like electropho-
resis (David et al. 2010, 2011, 2012).
Having demonstrated the ability to effectively KO 
gene function using CRISPR-Cas9 plasmids, future work 
regarding LAN may aim to either optimize this reported 
process or explore other genomic mechanisms that 
CRISPR-Cas9 can perform, such as transcriptional acti-
vation/repression or gene insertion (Cheng et  al. 2013; 
Gilbert et  al. 2013; Kimura et  al. 2014, 2015; Maeder 
et  al. 2013; Qi et  al. 2013), in terms of other cell types, 
such as primary cell lines or stem cells. Primary cell line 
targets are of interest because of the potential therapeu-
tic options it creates in regards to gene medicine and 
gene therapy applications, such as enhancing chronic 
wound healing (Badillo et  al. 2007; Branski et  al. 2009; 
Eming et  al. 1995; Eriksson et  al. 1998; Galeano et  al. 
2003). Stem cells are also of interest because of similar 
gene therapy potentials as well as applications related 
to transgenic animal generation. Specifically, a common 
method for creating chimeric transgenic animals involves 
genetic modification of stem cells prior to introduction 
to the blastocyst (Guo et al. 2014; Murayama et al. 2015; 
Ohtsuka et al. 2012; Polejaeva and Mitalipov 2013). The 
methods used to genetically modify these stem cells (i.e. 
electroporation, liposomal reagents) are characteristically 
Fig. 4 Lance array nanoinjection delivers CRISPR DNA for gene expression knock out. The percentage of GFP negative cells within the viable popu-
lation is plotted for each experimental group (mean and SEM). Controls include non-treated control (NTC), DNA background control (BC), negative 
electrical exposure control (NC), and DNA diffusion control (DC). Fully injected samples include cells injected once or three times with 1.5, 4.5, or 
6.0 mA as the current on the LAN for release of DNA into the cells. Statistically significant relationships are noted in Tables 2 and 3
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threatening to cell survivability and/or have lower trans-
fection rates (Hu et  al. 2013; Huang et  al. 2008; Mellott 
et  al. 2013). As discussed, LAN could provide a viable 
alternative in this area given the fact that genetic modi-
fications and cell survival can occur at high rates, and 
therefore requires further investigation.
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